



RJ Fitch

WuXiAppTec Business Leader

Address: Philadelphia, PA, US

Website: <http://www.rjfitch.net/>

Email: info@rjfitch.com

Raymond J. "RJ" Fitch is the Vice President Operations & General Manager of the WuXiAppTec Advanced Therapies site in Philadelphia, Pennsylvania. In his leadership roles with the company, he oversees all aspects of operations, including the strategic development of both business growth and operational development. Furthermore, RJ Fitch is involved in areas to insure the effective anticipation of operational and client growth when planning future facility expansion.

Mr. Fitch is responsible for leading the staff at three unique facilities at the Philadelphia site, focusing on operational and technological challenges impacting effective manufacturing and biological testing operations. His attention to detail and leadership qualities have led to a rapidly growing role at the company, which now includes a full oversight of the testing services business unit.

In addition to his activities with WuXiAppTec, Raymond Fitch engages with professional organizations such as the Parenteral Drug Association. In his free time, he enjoys staying active by running and gardening.

EXPERIENCE

WuXiAppTec

Apr 1, 2016 - Present

Vice President Operations & General Manager

Responsible for the Clinical and Commercial Contract Manufacturing and Testing for Gene Mediated Cell Therapy, Viral Vector and CAR-T cell therapy products in 3 facilities totaling 600 personnel.

Additional direct line responsibility for site HSE, Facilities Maintenance & Engineering, New facility start up activities, Biological Testing Activities, Quality and Supply Chain/Logistics.

Sanofi Pasteur

01/2014 - 04/2016

Vice President IO – Canadian Transformation Leader / Site Head

Executive expatriate transfer for compliance remediation (FDA – WL) of Canadian Vaccine manufacturing plant consisting of ~920 personnel & Operating budget of 165M euro.

Creation and launch of Site Transformation Office which was adopted as Pasteur global model for the creation of the "New Sanofi Pasteur", blending Operational Excellence with culture change.

Installation of project management process for refocus of site capital and resources to balance 9 facility remediation projects while working to restore supply.

Realigning Manufacturing and Industrial Performance organizations to delivery value of customer first priority while strengthening HSE and Compliance posture (Lifting of warning letter).

Genzyme - a Sanofi Company

11/2011 - 01/2014

Assoc. VP - General Manager Site Head

Presented with post acquisition Site turnaround opportunity and transferred to the Rare Disease division of Sanofi for supply, cost and quality remediation assignment. Mission consisted of building a culture and Organization that was predictable in Supply and Financial performance, self-sufficient in Compliance posture through Quality standard remediation and becoming a strategic partner with the Commercial Business Unit.

Directly accountable for all site operational aspects for 2 Rare Disease products starting with Master Cell Banking through formulation of Drug Substance. Total site Headcount ~350 persons, Operating budget is \$85M USD, revenue model of products is ~\$380M USD.

Installed transformational leadership model resulting in re-supply of critical products 2 years earlier than predicted, increased Bio-reactor capacity by 25%, improved Purification utilization by 114%, eliminated 98% of all Compliance backlog items, completed \$13M USD capital upgrade, constructed business case for ~\$75M USD long term investment in compliance and manufacturing capability, reduced standard cost by 23%.

EDUCATION

New York University - Stern School of Business

Sep 1, 2009 - Aug 1, 2011

Executive MBA

Executive MBA

Philadelphia University

Aug 1, 1992 - Dec 1, 1995

BS - Biology

Biology